Anti mlkl phospho s358

Manufactured by Abcam

Sourced in United States

Anti-MLKL (phospho S358) is a primary antibody that recognizes MLKL (mixed lineage kinase domain-like protein) phosphorylated at serine 358. MLKL is a key mediator of necroptosis, a form of programmed cell death.

Automatically generated - may contain errors

Lab products found in correlation

Anti β actin, by Merck Group (1 mentions) Image lab software, by Bio-Rad (1 mentions) Anti cleaved caspase 3, by Cell Signaling Technology (1 mentions) Anti cleaved parp, by Cell Signaling Technology (1 mentions) Anti mlkl, by Merck Group (1 mentions) Anti cleaved caspase 9, by Abcam (1 mentions) Chemidoc xrs system, by Bio-Rad (1 mentions) Anti normal rabbit igg, by Cell Signaling Technology (1 mentions) Anti cpt1a, by Abcam (1 mentions) Anti hsp60, by Santa Cruz Biotechnology (1 mentions) Anti lc3 1 2, by Novus Biologicals (1 mentions) Anti rab14, by Merck Group (1 mentions) Anti rab7a, by Merck Group (1 mentions) Anti actin, by Merck Group (1 mentions) Anti myc, by Merck Group (1 mentions) Anti gapdh, by Santa Cruz Biotechnology (1 mentions) Anti flag m2 hrp, by Merck Group (1 mentions) Anti hsv 1 icp0, by Santa Cruz Biotechnology (1 mentions) Anti mlkl, by Abcam (1 mentions) Z vad fmk, by Santa Cruz Biotechnology (1 mentions)

Spelling variants of this product

Anti-MLKL (23 citations) Phospho-MLKL (13 citations) Anti-phospho-MLKL (7 citations)

2 protocols using anti mlkl phospho s358

Immunoblotting Analysis of Cell Signaling Proteins

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cells were harvested and disrupted in IP lysis buffer (25 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP40, 1 mM EDTA, 5% glycerol; Thermo Scientific, MA, USA). Extracted proteins were separated by SDS-PAGE and transferred onto nylon membranes. Binding of primary antibodies was detected using peroxidase-conjugated secondary antibodies. Visualization was performed using the ChemiDoc XRS system with Image Lab software (Bio-Rad, CA, USA). Antibodies included anti-CPT1A, anti-cleaved caspase 9, anti-MLKL (phospho S358) (Abcam, MA, USA), anti-cleaved-PARP, anti-cleaved caspase 3, anti-normal rabbit IgG and anti-normal mouse IgG (Cell Signaling Technologies, MA, USA), anti-Rab14, anti-Rab7A, anti-MLKL and anti-β-actin (Sigma-Aldrich, Darmstadt, Germany), anti-HSP60 (Santa Cruz, CA, USA), and anti-LC3 I/II (Novus Biologicals, CA, USA).

Tan Z., Xiao L., Tang M., Bai F., Li J., Li L., Shi F., Li N., Li Y., Du Q., Lu J., Weng X., Yi W., Zhang H., Fan J., Zhou J., Gao Q., Onuchic J.N., Bode A.M., Luo X, & Cao Y. (2018). Targeting CPT1A-mediated fatty acid oxidation sensitizes nasopharyngeal carcinoma to radiation therapy. Theranostics, 8(9), 2329-2347.

+ Open protocol

+ Expand

Recombinant TNF-α and Smac Mimetic Induce Necroptosis

Check if the same lab product or an alternative is used in the 5 most similar protocols

Recombinant human TNF-α (Invivogen, rhtnf-a), Smac mimetic RMT5265 (also referred to as SMAC007) (Li et al., 2004 (link)), and zVAD (Z-VAD-FMK, Santa Cruz, sc-311561) (TSZ) were used at 10 ng/mL, 10 nM, and 20 μM, respectively. HSV-1 infections were performed at MOI = 5. Doxycycline (DOX) was used between 100 ng/mL and 500 ng/mL, as specified for each experiment. The RIPK3 inhibitor GSK840 (GlaxoSmithKline) was used at 3 μM and the MLKL inhibitor NSA (Calbiochem, #480073) was used at 0.2 μM. The following antibodies were used: Anti-FLAG M2-HRP (Sigma, A8592), Anti-MLKL (Abcam, ab184718), Anti-MLKL phospho S358 (Abcam, ab187091), Anti-Myc (Sigma, M4439), Anti-ITPK1 (GeneTex, GTX107974), Anti-HSV-1 ICP0 (Santa Cruz, 11060), Anti-GAPDH (Santa Cruz, sc-32233), Anti-IMMT (Protein Tech, 10179-1-AP), and Anti-Actin (Sigma, A2066).

Dovey C.M., Diep J., Clarke B.P., Hale A.T., McNamara D.E., Guo H., Brown NW J.r., Cao J.Y., Grace C.R., Gough P.J., Bertin J., Dixon S.J., Fiedler D., Mocarski E.S., Kaiser W.J., Moldoveanu T., York J.D, & Carette J.E. (2018). MLKL requires the inositol phosphate code to execute necroptosis. Molecular cell, 70(5), 936-948.e7.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!